-

ICON recognised as leading contract research organisation and employer by Scrip, Fierce Life Sciences, Financial Times and others

ICON finishes the second half of 2022 with an impressive line-up of awards that commend its healthcare intelligence work and status as an employer of choice, as independently judged by industry leaders and peers worldwide.

DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been recognised with a number of coveted business and industry awards over the second half of 2022 for delivering clinical research services, alongside specialist collaborations on data, analytics and digital healthcare.

The awards include the Best Contract Research Organisation – Full-Service Providers from Scrip, marking the second consecutive time after a win in 2021. Winners are chosen by an independent panel of industry experts, each chosen for their knowledge, objectivity and credibility.

ICON’s innovation capabilities were recognised as the company won the Data Analytics/Business Intelligence category in the Fierce Biotech Innovation Awards – Life Sciences 2022. The award was for ICON’s proprietary One Search tool, which uses intuitive, integrated workflow and artificial intelligence to provide access to multiple data sources to help identify optimum trial sites the first time.

In November, ICON was recognised in the Financial Times European Leader in Diversity 2023 Award List, ranked 80th out of 850 companies. The list is based on independent surveys of more than 100,000 employees across the continent. They were given the chance to evaluate their own employer’s diversity and inclusion practices and to give their perception of those adopted by other prominent employers in their respective industries. This follows recognition earlier in the year from Forbes as one of America’s Best Employers for Diversity for the second year running.

Overall, ICON was named on the 2022 Forbes World’s Best Employers List, which is based on a survey of 150,000 full-time and part-time workers from 57 countries.

ICON CEO Steve Cutler commented on the wide range of awards: “We are pleased to be recognised across the board by industry groups and leaders as we continue our focus on healthcare intelligence. To be recognised for innovations that drive clinical research forward, build an inclusive and diverse workplace and for strong collaboration with our customers is testament to the tireless efforts of our talented employees around the globe.”

Additional industry awards and recognition

ICON also won a total of four gold awards at the 2022 MarCom Awards from the Association of Marketing and Communication Professionals. ICON’s Creative & Digital Services and Insight and Evidence & Value teams won a gold award in the Print Media/Marketing/Promotion/Materials category, while the Creative & Digital Services and Patient Recruitment Solutions teams won a gold award in the Digital Media/Web Video/Marketing category. Additionally, ICON’s Creative & Digital Services and Insights, Evidence & Value teams won two gold awards in the categories of Communications/Public Relations/Other – Health Equity-Multicultural and Marketing/Promotion Campaign/Branding Refresh.

Technology company Medidata awarded ICON a Collaboration of the Year award for contributions to its RAVE Imaging Platform. This accolade recognises a unique partnership aimed at delivering a flexible and high-quality imaging trial experience for sites, readers and sponsors.

In October, 33 ICON staff members won awards or were finalists in numerous categories at the PharmaTimes Clinical Researcher of the Year Americas Awards, including Experienced Contract Research Associate, Clinical Trial Manager, Global Project Manager, Start-up—Single, Start-up—Team, Global Project Team, and Global Partnership Team.

Further success for ICON in the closing months of 2022 came from wins in the Sales Promotion category and the Poster Design category at the 2022 Health + Wellness Design Awards hosted by Graphic Design USA, as well as the Established Irish Investor in Asia Award from Asia Matters.

A full list of ICON’s industry awards can be viewed at www.iconplc.com/awards.

About ICON plc

ICON is a world-leading healthcare intelligence and clinical research organisation. From molecule to medicine, we advance clinical research providing outsourced development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health organisations. We develop new innovations, drive emerging therapies forward and improve patient lives. With headquarters in Dublin, Ireland, ICON employed approximately 41,150 employees in 113 locations in 53 countries as at September 30, 2022. For further information about ICON, visit: www.iconplc.com.

ICON/ICLR-G

Contacts

Claire Quinn (GMT time zone)
Corporate Communications, ICON plc
claire.quinn@iconplc.com
+353 87 4066091

Weber Shandwick (PR adviser)
Lisa Henry (GMT time zone)
+447785 458203
lhenry@webershandwick.com

ICON plc

NASDAQ:ICLR

Release Versions

Contacts

Claire Quinn (GMT time zone)
Corporate Communications, ICON plc
claire.quinn@iconplc.com
+353 87 4066091

Weber Shandwick (PR adviser)
Lisa Henry (GMT time zone)
+447785 458203
lhenry@webershandwick.com

Social Media Profiles
More News From ICON plc

ICON and Its Employees Recognised as Clinical Research Industry Leaders, and for Innovation and Progress in Sustainability

DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been honoured in the first half of 2025 with a number of business awards, recognising the company’s leadership position in the clinical research industry, cutting-edge innovation, its efforts in inclusion and sustainability, and as an employer of choice. Acknowledging ICON’s leadership in the application of innovative AI technologies in the industry, the organisation...

Global ICON survey shows need for more efficient obesity clinical trial design to realise full potential of next-gen multi-indication therapies

DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today released the findings of a survey of 155 biotech and pharma professionals from across the US and Europe focusing on multi-indication cardiometabolic R&D for therapies targeting obesity and its comorbidities. Multi-indication studies are clinical trials that test how a treatment works for more than one condition or disease. As researchers uncover the pote...

Biomarker and Trial Optimisation Needed to Drive R&D Progress in Alzheimer’s and Related Disorders – ICON Survey

DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today released the findings of a survey of over 120 biotech and pharma professionals developing treatments for neurodegenerative disorders. The findings indicate that, despite recent successes in developing disease modifying treatments for Alzheimer's, persistent challenges that remain in neurodegenerative clinical trials can be mitigated by underutilised trial me...
Back to Newsroom